Acceleron Pharma Inc
XLRNDelisted- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001280600
Acceleron Pharma Inc was delisted in 2021; its insiders filed their last Form 4 on Nov 22, 2021; 333 institutions reported holding it in 13F filings for Q3 2021, worth $9.22B in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Acceleron Pharma Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Acceleron Pharma Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| McLaughlin Kevin F | SVP, CFO and Treasurer | 0 | Nov 22, 2021 | 0 |
| Kearney Terrence C | Director | 0 | Nov 22, 2021 | 0 |
| Zakrzewski Joseph S | Director | 0 | Nov 22, 2021 | 0 |
| Kango Sujay | EVP, Chief Commercial Officer | 0 | Nov 22, 2021 | 0 |
| Nader Francois | Director | 0 | Nov 22, 2021 | 0 |
| MCCOURT Thomas A | Director | 0 | Nov 22, 2021 | 0 |
| Smith Karen L. | Director | 0 | Nov 22, 2021 | 0 |
| Dable Habib J | CEO and President | 0 | Nov 22, 2021 | 0 |
| Hamill Laura | Director | 0 | Nov 22, 2021 | 0 |
| Veness Adam M | SVP, General Counsel and Sec. | 0 | Nov 22, 2021 | 0 |
| Backstrom Jay T. | EVP, Research and Development | 0 | Nov 22, 2021 | 0 |
| Malik Kemal | Director | 0 | Nov 22, 2021 | 0 |
| Hite Christopher | Director | 0 | Nov 22, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 27, 2021 (view filing) | Sep 27 | Same day | Kango SujayEVP, Chief Commercial Officer | SSale | −5.00K | $175.00 | −$875.0K | −21.3%18.5K after | |
| Sep 24, 2021 (view filing) | Sep 23-24 | 1 day | McLaughlin Kevin FSVP, CFO and Treasurer | SSale | −25.0K | $160.33 | −$4.01M | −70.1%10.7K after | 3 lots |
| Sep 22, 2021 (view filing) | Sep 21 | 1 day | Veness Adam MSVP, General Counsel and Sec. | SSale | −6.65K | $150.05 | −$997.8K | −26.0%18.9K after | |
| Sep 22, 2021 (view filing) | Sep 21 | 1 day | Kango SujayEVP, Chief Commercial Officer | SSale | −5.00K | $150.03 | −$750.1K | −21.3%18.5K after | |
| Sep 9, 2021 (view filing) | Sep 8-9 | 1 day | Veness Adam MSVP, General Counsel and Sec. | SSale | −1.41K | $130.00 | −$183.7K | −6.9%18.9K after | 2 lots |
| Jul 2, 2021 (view filing) | Jul 1-2 | 1 day | Dable Habib JCEO and President | SSale | −100.0K | $126.83 | −$12.7M | −50.4%98.5K after | 8 lots |